OBJECTIVE: To determine the hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at tertiary care teaching hospital in Addis Ababa, Ethiopia.
METHODS: A facility-based cross-sectional study was conducted to evaluate hematological, clinical, cytogenetic and molecular profiles of confirmed CML patients at TASH from August 2021 to December 2022. A structured questionnaire was used to collect the patients\' sociodemographic information, medical history and physical examination, and blood samples were also collected for hematological, cytogenetic and molecular tests. Descriptive statistics were used to analyze the sociodemographic, hematological, clinical, cytogenetic and molecular profiles of the study participants.
RESULTS: A total of 251 confirmed new CML patients were recruited for the study. The majority of patients were male (151 [60.2%]; chronic (CP) CML, 213 [84.7%]; and had a median age of 36 years. The median (IQR) WBC, RBC, HGB and PLT counts were 217.7 (155.62-307.4) x103/µL, 3.2 (2.72-3.6) x106/µL, 9.3 (8.2-11) g/dl and 324 (211-499) x 103/µL, respectively. All patients had leukocytosis, and 92.8%, 95.6% and 99.2% of the patients developed anemia, hyperleukocytosis and neutrophilia, respectively. Fatigue, abdominal pain, splenomegaly and weight loss were the common signs and symptoms observed among CML patients. Approximately 86.1% of the study participants were Philadelphia chromosome positive (Ph+) according to fluorescence in situ hybridization (FISH). P210, the major breakpoint protein, transcript was detected by both qualitative polymerase chain reaction (PCR) and quantitative real time polymerase chain reaction (PCR).
CONCLUSIONS: During presentation, most CML patients presented with hyperleukocytosis, neutrophilia and anemia at TASH, Addis Ababa. Fatigue, abdominal pain, splenomegaly and weight loss were the most common signs and symptoms observed in the CML patients. Most CML patients were diagnosed by FISH, and p120 was detected in all CML patients diagnosed by PCR. The majority of CML patients arrive at referral center with advanced signs and symptoms, so better to decentralize the service to peripheral health facilities.
目的:为了确定血液,临床,亚的斯亚贝巴三级护理教学医院确认的CML患者的细胞遗传学和分子谱,埃塞俄比亚。
方法:进行了一项基于设施的横断面研究,以评估血液学,临床,2021年8月至2022年12月在TASH确诊的CML患者的细胞遗传学和分子谱。使用结构化问卷收集患者的社会人口统计信息,病史和体格检查,还收集了血液样本进行血液学检查,细胞遗传学和分子测试。描述性统计被用来分析社会人口统计学,血液学,临床,研究参与者的细胞遗传学和分子谱。
结果:共招募了251名确诊的新CML患者进行研究。大多数患者为男性(151[60.2%];慢性(CP)CML,213[84.7%];中位年龄为36岁。WBC中位数(IQR),红细胞,HGB和PLT计数为217.7(155.62-307.4)x103/微升,3.2(2.72-3.6)x106/微升,9.3(8.2-11)g/dl和324(211-499)x103/微升,分别。所有患者都有白细胞增多症,92.8%,95.6%和99.2%的患者出现贫血,高白细胞增多症和嗜中性粒细胞增多症,分别。疲劳,腹痛,脾肿大和体重减轻是CML患者的常见体征和症状.根据荧光原位杂交(FISH),约有86.1%的研究参与者为费城染色体阳性(Ph)。P210,主要的断点蛋白,通过定性聚合酶链反应(PCR)和定量实时聚合酶链反应(PCR)检测转录本。
结论:在演示期间,大多数CML患者出现高白细胞增多,中性粒细胞增多症和贫血,亚的斯亚贝巴。疲劳,腹痛,脾肿大和体重减轻是CML患者中最常见的体征和症状.大多数CML患者通过FISH诊断,在所有诊断为CML的患者中通过PCR检测到p120。大多数CML患者到达转诊中心时出现晚期症状和体征,所以更好地将服务下放给周边卫生设施。